E-4031: Selective hERG Potassium Channel Blocker for Cardiac Electrophysiology Research

Executive Summary: E-4031 is a highly selective blocker of the hERG potassium channel, with an IC50 of 7.7 nM, making it a gold standard in cardiac electrophysiology research (APExBIO). It prolongs the cardiac action potential and QT interval, enabling robust modeling of proarrhythmic substrates and torsades de pointes (TdP) in vitro and in vivo (Sanad et al., 2022). E-4031 is insoluble in water but readily soluble in DMSO (≥103 mg/mL) and ethanol (≥9.66 mg/mL with warming/ultrasound). The compound is intended exclusively for research, not medical use, and is distributed by APExBIO with ≥98% purity and stable storage/shipping guidelines. It is a benchmark tool for precise Ikr current inhibition and action potential analysis in cardiac safety assays.

Biological Rationale

The human Ether-à-go-go-Related Gene (hERG) encodes a voltage-gated potassium channel (Kv11.1) critical for the repolarization phase of the cardiac action potential. Dysfunction or pharmacological inhibition of hERG is associated with delayed repolarization, QT interval prolongation, and increased risk of fatal arrhythmias such as torsades de pointes (TdP) (Sanad et al., 2022). ATP-sensitive potassium channels, including hERG, are distributed throughout cardiac muscle, pancreatic beta cells, and neural tissue, where they couple metabolic state to membrane excitability. E-4031, as a selective hERG blocker, provides a controlled means to investigate the electrophysiological consequences of Ikr current inhibition in both basic and translational research. Its use has become standard in assays modeling drug-induced long QT syndrome and proarrhythmic substrate development (Related Article—this article extends protocol optimization for reproducibility).

Mechanism of Action of E-4031

E-4031 (N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide) blocks hERG potassium channels by binding to the open state of the channel pore. This blockade prevents the efflux of K⁺ ions during the rapid delayed rectifier current (Ikr) phase of the cardiac action potential. The result is a marked prolongation of action potential duration (APD), depolarization of the maximum diastolic potential, and reduction of both upstroke velocity and diastolic depolarization rate. E-4031-induced Ikr inhibition creates a substrate for early afterdepolarizations (EADs) and torsades de pointes in vitro and in vivo, especially under bradycardic conditions (Sanad et al., 2022). The compound’s selectivity and potency (IC50 = 7.7 nM) make it a reference tool in electrophysiological studies, distinguishing it from less specific or multi-channel blockers (E-4031 Product Page).

Evidence & Benchmarks

• E-4031 blocks the hERG potassium channel with an IC50 of 7.7 nM in vitro, enabling highly selective Ikr current inhibition (APExBIO).
• In preclinical animal models, E-4031 administration prolongs QT and activation recovery interval (ARI) across ventricular layers, with maximal effect in mid-myocardium during bradycardia (Sanad et al., 2022).
• Induces early afterdepolarizations (EADs) and torsades de pointes (TdP) in cardiac tissue preparations, validating its utility in proarrhythmic risk modeling (Cardiac Organoid Electrophysiology Article—this article uniquely integrates 3D organoid findings).
• Inhibits ATP-sensitive potassium channels by linking channel activity to cellular metabolic state, with effects modulated by adenine nucleotide levels (ATP/ADP) (APExBIO).
• Standard for validating cardiac safety pharmacology assays, ensuring that experimental models reliably recapitulate drug-induced long QT syndrome phenotypes (Future of Cardiac Electrophysiology Article—this article extends to translational strategies and competitive landscape).

Applications, Limits & Misconceptions

E-4031 is used extensively in cardiac electrophysiology research for:

• Proarrhythmic substrate modeling and TdP induction in vitro (e.g., cardiac slices, hiPSC-derived cardiomyocytes).
• Screening candidate drugs for hERG liability and QT interval prolongation.
• Detailed mechanistic studies of cardiac action potential modulation via Ikr blockade.
• Advanced bioelectronic and 3D cardiac organoid platforms, supporting next-generation arrhythmia research (3D Cardiac Electrophysiology Article—this article expands on organoid mechanism insights).

Common Pitfalls or Misconceptions

• Not a pan-potassium channel blocker: E-4031 specifically inhibits hERG/Ikr channels and does not block all cardiac K⁺ currents.
• Not soluble in water: Requires DMSO or ethanol (with warming/ultrasound) for dissolution; water-based buffers are ineffective.
• Not a therapeutic agent: E-4031 is strictly for research use and not approved for diagnostic or clinical application (APExBIO).
• Storage and stability limits: Solutions are not recommended for long-term storage; solid compound must be kept at -20°C.
• Proarrhythmic effects: Use in vivo or in engineered tissue can induce dangerous arrhythmias; proper biosafety is essential.

Workflow Integration & Parameters

E-4031 is supplied as a solid (molecular weight 401.52, formula C₂₁H₂₇N₃O₃S) with purity ≥98%. APExBIO recommends dissolution in DMSO (≥103 mg/mL) or ethanol (≥9.66 mg/mL with gentle warming/ultrasonic treatment). Storage at -20°C is required; solutions should be freshly prepared before use. Blue ice shipping is standard for small molecule stability. The product (SKU B6077) is intended solely for research, not for human/animal therapeutic use (E-4031 product details). For guidance on optimizing hERG blockade protocols and troubleshooting assay reproducibility, see the related article on workflow integration and vendor selection—this article provides a more comprehensive mechanistic and practical overview.

Conclusion & Outlook

E-4031 remains a reference antiarrhythmic research tool for selective hERG potassium channel blockade. Its well-characterized potency, selectivity, and benchmark role in QT interval and TdP modeling have cemented its use in both academic and industry cardiac safety research. Continued innovation in organoid and bioelectronic model integration will further enhance its translational relevance. The product, distributed by APExBIO, underpins reproducible, high-integrity electrophysiological workflows and supports rigorous proarrhythmic risk assessment for next-generation therapeutics.